Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash & Current Investments (2018 - 2025)

Silence Therapeutics' Cash & Current Investments history spans 8 years, with the latest figure at $85.1 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 42.23% to $85.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $85.1 million, a 42.23% decrease, with the full-year FY2025 number at $85.1 million, down 42.23% from a year prior.
  • Cash & Current Investments hit $85.1 million in Q4 2025 for Silence Therapeutics, down from $122.4 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for SLN hit a ceiling of $193.8 million in Q1 2024 and a floor of $62.8 million in Q2 2023.
  • Historically, Cash & Current Investments has averaged $110.3 million across 5 years, with a median of $99.2 million in 2021.
  • Biggest five-year swings in Cash & Current Investments: surged 658.63% in 2021 and later plummeted 42.23% in 2025.
  • Tracing SLN's Cash & Current Investments over 5 years: stood at $99.5 million in 2021, then dropped by 16.16% to $83.4 million in 2022, then dropped by 19.21% to $67.4 million in 2023, then surged by 118.55% to $147.3 million in 2024, then plummeted by 42.23% to $85.1 million in 2025.
  • Business Quant data shows Cash & Current Investments for SLN at $85.1 million in Q4 2025, $122.4 million in Q3 2025, and $186.6 million in Q2 2025.